A5024251435- Advanced Causal Inference Techniques
- Workplace Health and Well-being
- Lung Cancer Treatments and Mutations
- SARS-CoV-2 and COVID-19 Research
- Lung Cancer Research Studies
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Treatment and Pharmacology
- Statistical Methods and Bayesian Inference
- Employment and Welfare Studies
- Vaccine Coverage and Hesitancy
- Occupational and environmental lung diseases
- Neuroblastoma Research and Treatments
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Statistical Methods and Inference
- Cancer therapeutics and mechanisms
- Pleural and Pulmonary Diseases
- Cancer Immunotherapy and Biomarkers
- Statistical Methods in Clinical Trials
- Cancer Genomics and Diagnostics
- Cell death mechanisms and regulation
- Climate Change and Health Impacts
- Pharmaceutical Practices and Patient Outcomes
- SARS-CoV-2 detection and testing
- Healthcare Policy and Management
Université Laval
2016-2025
Centre hospitalier de l'Université Laval
2017-2024
Centre hospitalier universitaire de Québec
2017-2024
Hôpital du Saint-Sacrement
2021-2024
The Quebec Population Health Research Network
2016-2024
Centre de Médecine Préventive
2024
Novem (Netherlands)
2023
Institut National de Santé Publique du Québec
2022
University of Oxford
2010-2021
Churchill Hospital
2009-2021
This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients advanced non-small-cell lung cancer (NSCLC).
The Canadian coronavirus disease 2019 (COVID-19) immunization strategy deferred second doses and allowed mixed schedules. We compared 2-dose vaccine effectiveness (VE) by type (mRNA and/or ChAdOx1), interval between doses, time since dose in 2 of Canada's larger provinces.
PURPOSE: So far there are no published data on optimal duration of chemotherapy for advanced non–small-cell lung cancer (NSCLC); six or more courses usually recommended. We have carried out a multicenter randomized trial comparing three versus chemotherapy. PATIENTS AND METHODS: Patients with stage IIIb IV NSCLC were at start treatment to receive either mitomycin 8 mg/m 2 (courses 1, 2, 4, and 6), vinblastine 6 , cisplatin 50 (MVP) every 21 days. Treatment was stopped early in both arms...
The base excision repair (BER) pathway is essential for the removal of DNA bases damaged by alkylation or oxidation.A key step in BER processing an apurinic/apyrimidinic (AP) site intermediate AP endonuclease.The major endonuclease human cells (APE1, also termed HAP1 and Ref-1) accounts .95% total activity, protection against toxic effects several classes damaging agents.Moreover, APE1 overexpression has been linked to radio-and chemo-resistance tumors.Using a newly developed high-throughput...
Tumor necrosis factor (TNF) alpha is a key player in the tumor microenvironment and involved pathogenesis of breast cancer. Etanercept recombinant human soluble p75 TNF receptor that binds to TNF-alpha renders it biologically unavailable. In current study, we sought determine toxicity, biological activity, therapeutic efficacy metastatic cancer.We initiated Phase II, nonrandomized, open-labeled study patients with progressive cancer refractory conventional therapy (Phase I toxicity data were...
Background30-day mortality might be a useful indicator of avoidable harm to patients from systemic anticancer treatments, but data for this are limited. The Systemic Anti-Cancer Therapy (SACT) dataset collated by Public Health England allows the assessment factors affecting 30-day in national patient population. aim first study based on SACT was establish benchmarks breast and lung cancer receiving England, start identify where care could improved.MethodsIn population-based study, we...
PURPOSE; Evaluation of the communication and informed consent process in phase I clinical trial interviews to provide authentic, practice-based content for inclusion a skills training intervention health care professionals.Seventeen oncologists 52 patients from five United Kingdom cancer centers consented recording discussions. Following each consultation, clinicians completed questionnaires indicating areas they felt had discussed, researchers conducted semistructured with examining their...
ABSTRACT Background The Canadian COVID-19 immunization strategy deferred second doses and allowed mixed schedules. We compared two-dose vaccine effectiveness (VE) by type (mRNA and/or ChAdOx1), interval between doses, time since dose in two of Canada’s larger provinces. Methods Two-dose VE against infections hospitalizations due to SARS-CoV-2, including variants concern, was assessed May 30 October 2, 2021 using test-negative designs separately conducted among community-dwelling adults...
Importance The Omicron variant is phylogenetically and antigenically distinct from earlier SARS-CoV-2 variants the original vaccine strain. Protection conferred by prior infection against reinfection, with without vaccination, requires quantification. Objective To estimate protection reinfection hospitalization heterologous non-Omicron and/or up to 3 doses of an ancestral, Wuhan-like messenger RNA (mRNA) vaccine. Design, Setting, Participants This test-negative, population-based case-control...
Capecitabine, an oral fluoropyrimidine carbamate, was designed to generate 5-fluorouracil preferentially at the tumour site. This randomised, phase II trial evaluated efficacy and safety of capecitabine or paclitaxel in patients with anthracycline-pretreated metastatic breast cancer. Outpatients locally advanced and/or cancer whose disease unresponsive resistant anthracycline therapy were randomised 3-week cycles intermittent (1255 mg m−2 twice daily, days 1–14, (22 patients)) a reference...
Enhanced tumor cell survival through expression of inhibitors apoptosis (IAP) is a hallmark cancer. Survivin, an IAP absent from most normal tissues, overexpressed in many malignancies and associated with poorer prognosis. We report the first-in-human dose study LY2181308, second-generation antisense oligonucleotide (ASO) directed against survivin mRNA.A dose-escalation evaluating safety, pharmacokinetics, pharmacodynamics LY2181308 administered intravenously for 3 hours as loading on...
Background Single gene tests to predict whether cancers respond specific targeted therapies are performed increasingly often. Advances in sequencing technology, collectively referred as next generation (NGS), mean the entire cancer genome or parts of it can now be sequenced at speed with increased depth and sensitivity. However, translation NGS into routine care has been slow. Healthcare stakeholders unclear about clinical utility concerned could an expensive addition diagnostics, rather...
Abstract Background The diagnosis of neuroendocrine neoplasms (NENs) is often delayed. This first UK population-based epidemiological study NENs compares outcomes with non-NENs to identify any inequalities. Methods Age-standardised incidence rate (ASR), 1-year overall survival, hazard ratios and standardised mortality rates (SMRs) were calculated for all malignant diagnosed 2013–2015 from national Public Health records. Comparison assessed survival (1YS) association between at stage IV...
The robust Poisson method is becoming increasingly popular when estimating the association of exposures with a binary outcome. Unlike logistic regression model, yields results that can be interpreted as risk or prevalence ratios. In addition, it does not suffer from frequent nonconvergence problems such most common implementations maximum likelihood estimators log-binomial model. However, using distribution to model outcome may seem counterintuitive. Methodologic papers have often presented...